Unhealthy report for Zetia and Vytorin

Jennifer Collins Nov 16, 2009
HTML EMBED:
COPY

Unhealthy report for Zetia and Vytorin

Jennifer Collins Nov 16, 2009
HTML EMBED:
COPY

TEXT OF STORY

Bill Radke:A new study is raising more questions about Merck’s cholesterol drugs. The results were presented yesterday at the annual meeting of the American Heart Association. Marketplace’s Jennifer Collins reports.


Jennifer Collins: The study compared Merck drug Zetia to another drug, Niaspan. That’s made by rival Abbott Laboratories, and Abbott sponsored this study.

Researchers found that Zetia didn’t shrink the plaque in some arteries as much as Niaspan did. Zetia users may also have suffered more heart attacks. That may not exactly prompt you to:

ZETIA AD: Ask your doctor if Zetia’s right for you.

And may make you more likely to ask for Niaspan. Analyst Les Funtleyder of Miller Tabak says that’s exactly what the study was designed to do:

LES FUNTLEYDER: It sort of is a marketing study. You want to prove your drug is better than the other drug.

Trouble is, this is yet another in a string of unfavorable results for Zetia. Prescription rates of the drug have already fallen more than 20 percent.

Funtleyder: The question is how much worse it gets.

Experts also say the study is too small to draw firm conclusions. Larger studies are in the works, but results won’t be known for several years.

I’m Jennifer Collins for Marketplace.

We’re here to help you navigate this changed world and economy.

Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.

In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.

Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.